Read this expert commentary to gain insights into the rationale and latest clinical evidence for combination strategies with EGFR TKIs for the first-line treatment of EGFR-mutated advanced NSCLC.
What I want my colleagues to know about treating patients with advanced NSCLC and uncommon EGFR mutations, including future directions targeting these mutations.
In this commentary, a lung cancer expert highlights advances from ASCO 2022 in the management of EGFR-mutated NSCLC with acquired resistance to first-line EGFR TKI therapy using rational combination regimens composed of third-generation EGFR TKIs, EGFR monoclonal antibodies, bispecific antibodies, and antibody–drug conjugates.
Review this slideset from a workshop series on optimal management of EGFR-mutated advanced NSCLC, including expert insights on promising investigational agents and combination therapy.
Download this focused resource for a quick guide to EGFR-targeted agents used in current practice for patients with advanced NSCLC and EGFR mutations, including exon 20 insertions.
Download this clinical resource for expert recommendations from May 2022 on molecular testing for targetable genetic alterations in patients with advanced NSCLC.
Download this short resource for a summary of ongoing clinical trials and active areas of research in the setting of EGFR-mutated NSCLC.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.